Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr).
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
13
03
2022
pubmed:
11
4
2022
medline:
7
5
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Biological therapies are valuable treatments for severe psoriasis. Children aged under 12 years are underrepresented in therapeutic trials for these drugs. The objective of the 'BiPe Jr' cohort study was to evaluate the drug survival, effectiveness, tolerance and switching patterns of biological therapies in children under 12 years of age with psoriasis. We conducted a multicentre retrospective study of children with psoriasis who received at least one injection of a biological agent, even off-licence, before the age of 12 years in France and Italy, collecting the data between April and August 2021. The data collected were from March 2012 up to August 2021. In total, 82 children (mean age: 9.1 years; females: 61.0%) received 106 treatments. The drugs administered were adalimumab (n = 49), etanercept (n = 37), ustekinumab (n = 15), anakinra (n = 2), infliximab (n = 2) and secukinumab (n = 1). The most common form of psoriasis was plaque psoriasis (62.9%). The Physician Global Assessment and the Psoriasis Area Severity Index (PASI) scores decreased significantly from baseline to 3 months after treatment initiation for the three main biological drugs; PASI went from 14.1 ± 9.4 to 4.1 ± 11.3 for adalimumab (p = 0.001), 14.9 ± 9.3 to 5.1 ± 4.0 for etanercept (p = 0.002) and 11.6 ± 8.3 to 2.6 ± 2.2 for ustekinumab (p = 0.007). A trend towards higher 2-year maintenance rates was observed for ustekinumab and adalimumab, compared with etanercept (p = 0.06). 52 children discontinued their biological therapy, most frequently due to inefficacy (n = 28) and remission (n = 14). Seven serious adverse events (SAEs) were reported, including four severe infections. Our analyses of drug survival and treatment patterns, combined with those of previous studies conducted in older children, indicate that there is a trend towards higher 2-year survival rates of ustekinumab and adalimumab. The SAEs identified were rare, but highlight the need for increased vigilance concerning infections. Overall, the biological therapies showed good effectiveness and safety profiles when used in daily practice for the treatment of young children with psoriasis.
Identifiants
pubmed: 35397731
doi: 10.1007/s40272-022-00501-6
pii: 10.1007/s40272-022-00501-6
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-292Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Nast A, Gisondi P, Ormerod AD, et al. European S3—guidelines on the systemic treatment of psoriasis vulgaris—update 2015–Short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–94.
doi: 10.1111/jdv.13354
Mahé E, Amy-De La-Bretêque M, Phan C. Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients. Expert Rev Clin Pharmacol. 2021;14:807–19.
doi: 10.1080/17512433.2021.1911641
Menter A, Cordoro KM, Davis DMR, et al. Joint American academy of dermatology-national psoriasis foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161–201.
doi: 10.1016/j.jaad.2019.08.049
Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents—short version part 2. J Dtsch Dermatol Ges. 2019;17:959–73.
pubmed: 31538739
Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017;176:1339–54.
doi: 10.1007/s00431-017-2985-x
Charbit L, Mahé E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174:1118–21.
doi: 10.1111/bjd.14326
Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153:1147–57.
doi: 10.1001/jamadermatol.2017.3029
Mahé E, Corgibet F, Maccari F, et al. Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant. Ann Dermatol Venereol. 2020;147:429–38.
doi: 10.1016/j.annder.2020.01.021
Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–51.
doi: 10.1056/NEJMoa066886
Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594–603.
doi: 10.1016/j.jaad.2015.07.002
Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40–9.
doi: 10.1016/S0140-6736(17)31189-3
Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35:938–47.
doi: 10.1111/jdv.17002
Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664–72.
doi: 10.1111/bjd.19018
Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1984–92.
doi: 10.1111/jdv.15579
Lamer A, Laurent G, Pelayo S, et al. Exploring patient path through Sankey diagram: a proof of concept. Stud Health Technol Inform. 2020;270:218–22.
pubmed: 32570378
Roux J. Parcours de soins des patients atteints de sclérose en plaques à partir des données médico-administratives en France. 2018. https://tel.archives-ouvertes.fr/tel-02379451 .
Wan J, Shin DB, Gelfand JM. Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis. Pediatr Dermatol. 2021;38:1169–77.
doi: 10.1111/pde.14781
Di Lernia V, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther. 2019;32:e13091.
doi: 10.1111/dth.13091
Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2017;18:1–3.
Phan C, Beauchet A, Burztejn AC, et al. Evaluation of children with psoriasis from the BiPe cohort: are patients using biotherapies in real life eligible for phase III clinical studies? Paediatr Drugs. 2019;21:169–75.
doi: 10.1007/s40272-019-00335-9
Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280–7.
doi: 10.1016/j.jaad.2015.09.056
Richard MA; Groupe de recherche sur le psoriasis de la Société Française de Dermatologie. Psoriasis: évaluation initiale et bilan thérapeutique pratique. Ann Dermatol Venereol. 2019;146:440–9.
Mahé E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28:151–9.
doi: 10.1111/jdv.12066
Wu MY, Yu CL, Yang SJ, Chi CC. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis. J Am Acad Dermatol. 2020;82:101–9.
doi: 10.1016/j.jaad.2019.07.103
Mazhar F, Battini V, Pozzi M, et al. Changes in anthropometric parameters after anti-TNFα therapy in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2020;34:649–68.
doi: 10.1007/s40259-020-00444-9
Phan C, Beauchet A, Reguiai Z, et al. Switching biologics in children with psoriasis: results from the BiPe cohort. Pediatr Dermatol. 2022;39:35–41.
doi: 10.1111/pde.14845
Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther. 2021;34:e14584.
doi: 10.1111/dth.14584
Sherman S, Solomon Cohen E, Amitay-Laish I, et al. IL-17A inhibitor switching—efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol. 2019;99:769–73.
doi: 10.2340/00015555-3200
Chiricozzi A, Conti A, Burlando M, et al. Switching from secukinumab to ustekinumab in psoriasis patients: results from a multicenter experience. Dermatol Basel Switz. 2019;235:213–8.
doi: 10.1159/000497274
Damiani G, Conic RRZ, de Vita V, et al. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther. 2019;32:e12793.
doi: 10.1111/dth.12793
Tai YC, Tsai TF. Switching biologics in psoriasis—practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13:493–503.
doi: 10.1080/17512433.2020.1767590
Badaoui A, Tounian P, Mahé E. Psoriasis and metabolic and cardiovascular comorbidities in children: a systematic review. Arch Pediatr. 2019;26:86–94.
doi: 10.1016/j.arcped.2018.12.005
Phan K, Lee G, Fischer G. Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis. Pediatr Dermatol. 2020;37:661–9.
doi: 10.1111/pde.14208